CytoDyn is a biotech company focused on developing new therapies for combating infection with immune deficiency viruses and other antibody applications. Its proprietary drug candidate PRO 140 is a humanized monoclonal antibody which has demonstrated the ability to block the entry of HIV virus into human white cells. PRO 140 has completed phase I and phase 2a human clinical trials. For further information, visit the company’s Web site at www.cytodyn.com

EBD Group’s Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco for this important event.

Let us hear your thoughts below: